Mironid Presents Translational Data in Oral Presentation at the ...
Mironid Presents Translational Data in Oral Presentation at the European Renal Association Congress LoAc® compound… OTT. Call Me Bae: Ananya Panday's premiere ...
Mironid Completes Successful Innovate UK Grant for ...
“The data generated through this Innovate UK grant has significantly ... We look forward to presenting our research, with Catherine (Cass) [...].
Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate ...
Oral Presentation Details: Title: ZW220, a NaPi2b-directed topoisomerase I inhibitor Antibody-Drug Conjugate, demonstrates compelling ...
Our lead programme aims to treat Autosomal Dominant Polycystic Kidney Disease (ADPKD), which is characterized by uncontrolled growth of fluid-filled cysts ...
Mironid® extends Series A round raising £35 million to date for ...
Mironid is a biopharmaceutical company developing small molecule therapeutics for the treatment of life-threatening hereditary kidney disease.
The goal is to generate novel and differentiated therapies for a range of diseases with high unmet medical need. Global leader in PDE therapeutic development.